Active Ingredient(s):Fam-trastuzumab Deruxtecan-nxki FDA Approved: * December 20, 2019 Pharm Company: *DAIICHI SANKYO Category:Cancer
Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. Trastuzumab binds to and blocks signaling through epidermal growth factor...
* May have multiple approval dates, manufacturers, or labelers.
Enhertu 100 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution